Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA Stroke Trial

被引:109
|
作者
Broderick, JP
Lu, M
Kothari, R
Levine, SR
Lyden, PD
Haley, EC
Brott, TG
Grotta, J
Tilley, BC
Marler, JR
Frankel, M
机构
[1] Univ Cincinnati, Dept Neurol, Cincinnati, OH 45267 USA
[2] Henry Ford Hlth Sci Ctr, Dept Biostat & Res Epidemiol, Detroit, MI USA
[3] Borgess Res Inst, Kalamazoo, MI USA
[4] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA
[5] Univ Calif San Diego, Stroke Ctr, San Diego, CA 92103 USA
[6] Univ Virginia Hlth Syst, Dept Neurol, Charlottesville, VA USA
[7] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA
[8] Univ Texas, Dept Neurol, Houston, TX USA
[9] Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA
[10] NINDS, Div Stroke & Trauma, Bethesda, MD 20892 USA
[11] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA
关键词
clinical trials; models; predictive; outcome; stroke; tissue plasminogen activator;
D O I
10.1161/01.STR.31.10.2335
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-We sought to identify the most powerful binary measures of the treatment effect of tissue plasminogen activator (tPA) in the National Institute of Neurological Disorders and Stroke (NINDS) rTPA Stroke Trial, Methods-Using the Classification and Regression Tree (CART) algorithm, we evaluated binary cut points and combination of binary cut points with the 4 clinical scales and head CT imaging measures in the NINDS tPA Stroke Trial at 4 times after treatment: 2 hours, 24 hours, 7 to 10 days, and 3 months. The first analysis focused on detecting evidence of "early activity" of tPA with the use of outcome measures derived from the 2-hour and 24-hour clinical and radiographic measures, The second analysis focused on longer-term outcome and "efficacy" and used outcome measures derived from 7- to 10-day and 3-month measures. After identifying the cut points with the ability to classify patients into the tPA and placebo groups using part I data from the trial, we then used data from part II of the trial to validate the results. Results-Of the 5 most powerful outcome measures for early activity of tPA, 4 involved the National Institutes of Health Stroke Scale (NIHSS) score at 24 hours or changes in the NIHSS score from baseline to 24 hours. The best overall single outcome measure was an NIHSS score less than or equal to 2 at 24 hours, which provided an odds ratio of 5.4 (95% CI, 2.4 to 12.1) and a projected sample size of 58 per treatment group assuming an alpha of 0.05 (2-sided test) and a power of 80% using part I data. The top 2 and 3 of the top 5 outcome measures for detecting the longer-term efficacy of tPA also involved the NIHSS score. A Rankin score of 0 or 1 at 3 months was the third most powerful outcome measure. Outcome measures identified by CART from part I data were not as sensitive in detecting the effectiveness of tPA when applied to part n data. Conclusions-Measures using the NIHSS and a Rankin score less than or equal to 1 were the most sensitive discriminators of the effectiveness of tPA in the NINDS tPA Stroke Trial compared with the other clinical and radiological measures. The outcome measures identified in this exploratory analysis (eg, NIHSS score less than or equal to 2 at 24 hours) would be best used as an outcome measure in future phase II trials of recanalization begun within the first 3 hours after stroke onset, with inclusion and exclusion criteria similar to those in the NINDS tPA Stroke Trial.
引用
收藏
页码:2335 / 2341
页数:7
相关论文
共 50 条
  • [1] Tissue plasminogen activator experience beyond the NINDS trial
    Torbey, M
    Moonis, M
    ANNALS OF NEUROLOGY, 1998, 44 (03) : 517 - 517
  • [2] Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial
    Ingall, TJ
    O'Fallon, WM
    Asplund, K
    Goldfrank, LR
    Hertzberg, VS
    Louis, TA
    Christianson, TJH
    STROKE, 2004, 35 (10) : 2418 - 2424
  • [3] Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial
    Hertzberg, Vicki
    Ingall, Timothy
    O'Fallon, William
    Asplund, Kjell
    Goldfrank, Lewis
    Louis, Thomas
    Christianson, Teresa
    CLINICAL TRIALS, 2008, 5 (04) : 308 - 315
  • [4] EVALUATION OF TISSUE PLASMINOGEN-ACTIVATOR (TPA) IN EMBOLIC STROKE
    CHEHRAZI, BB
    SIEBERT, AJ
    HEIN, L
    BROCK, J
    STROKE, 1988, 19 (01) : 133 - 133
  • [5] SAFETY AND POTENTIAL EFFICACY OF TISSUE PLASMINOGEN-ACTIVATOR (TPA) FOR STROKE
    BROTT, T
    HALEY, C
    LEVY, D
    BARSAN, W
    SHEPPARD, G
    BRODERICK, J
    REED, R
    MARLER, J
    STROKE, 1990, 21 (01) : 181 - 181
  • [6] Tissue Plasminogen Activator (tPA) and Matrix Metalloproteinases in the Pathogenesis of Stroke: Therapeutic Strategies
    Adibhatla, Rao Muralikrishna
    Hatcher, James F.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2008, 7 (03) : 243 - 253
  • [7] Tissue plasminogen activator (tPA) for ischemic stroke in patients aged ≥ 80 years
    Zhou, C.
    Zhu, L.
    Wu, J.
    Fang, S.
    ACTA NEUROLOGICA SCANDINAVICA, 2013, 128 (03): : e17 - e18
  • [9] Comparison of multistate Markov modeling with contemporary outcomes in a reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial
    Cassarly, Christy
    Martin, Renee H.
    Chimowitz, Marc
    Pena, Edsel A.
    Ramakrishnan, Viswanathan
    Palesch, Yuko Y.
    PLOS ONE, 2017, 12 (10):
  • [10] Tissue Plasminogen Activator Does Not Benefit Most Eligible Patients With Stroke
    Lansberg, Maarten G.
    Schwartz, Neil E.
    ARCHIVES OF NEUROLOGY, 2009, 66 (04) : 540 - 541